Related Experiment Video
Updated: Feb 6, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
The role of ketoconazole in current prostate cancer care
Vaibhav Patel1, Bobby Liaw2, William Oh3
1Division of Hematology and Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. vaibhav.patel@mountsinai.org.
Abstract:
Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor that has been used, off-label, as a second-line therapy for castration-resistant prostate cancer (CRPC). The drug has shown clinical efficacy without survival benefit. Despite not improving survival, ketoconazole has beneficial characteristics, such as its low cost, a relatively favourable toxicity profile compared with chemotherapy, and its efficacy both before and after chemotherapy. The approval of several new, highly effective treatments, including abiraterone acetate, enzalutamide, and apalutamide, warrants re-evaluation of the role of ketoconazole and other classic agents in achieving the optimal timing and sequencing of available agents to prolong survival and maintain patients' quality of life. In the current CRPC treatment landscape, we believe that ketoconazole can be considered in patients with nonmetastatic CRPC and in those with metastatic CRPC who do not respond to, tolerate, or have access to chemotherapy and other standard therapeutic options.
Insights
Ketoconazole, a CYP17A1 inhibitor, shows clinical efficacy for castration-resistant prostate cancer (CRPC) without improving survival. Its low cost and favorable toxicity profile support its use in specific CRPC patient groups.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor.
- It has been used off-label as a second-line therapy for castration-resistant prostate cancer (CRPC).
Purpose of the Study:
- To re-evaluate the role of ketoconazole in the current CRPC treatment landscape.
- To determine optimal timing and sequencing of ketoconazole with other agents to maintain quality of life.
Main Methods:
- Review of clinical efficacy and toxicity data for ketoconazole in CRPC.
- Comparison of ketoconazole with newer CRPC therapies like abiraterone acetate, enzalutamide, and apalutamide.
Main Results:
- Ketoconazole demonstrates clinical efficacy in CRPC but without a survival benefit.
- It offers a low cost and a favorable toxicity profile compared to chemotherapy.
- Efficacy is noted both before and after chemotherapy treatment.
Conclusions:
- Ketoconazole can be considered for nonmetastatic CRPC patients.
- It is a viable option for metastatic CRPC patients unresponsive to, intolerant of, or lacking access to standard therapies.
Related Concept Videos
Interdisciplinary Care: The Health Care Team-I
Physicians
The physician's primary responsibility is to diagnose illness and direct the medical or surgical treatment of the condition. The authority to admit patients to a healthcare agency or institution and practice care within that setting is granted to physicians by the healthcare agency or institution...
Interdisciplinary Care: The Health Care Team-II
Physical Therapist
A physical therapist (PT) aims to restore function or prevent additional impairment in a patient following an injury or disease. Massage, heat, cold, water, sonar waves, exercises, and electrical stimulation are some treatments used by PTs to treat...
Continuing Care
Standards of Care I
Electrical Current
Ostomy Care
An ostomy is a surgical procedure that creates an artificial opening from the intestines to the outside of the body, allowing for the rerouting of effluent. This opening is known as a stoma. A stoma usually protrudes above the skin surface, appearing pink or red, moist, and round, and it lacks nerve sensations.
There are different types of ostomies, including colostomies, ileostomies, and urostomies:

